Zotepine: a clinical review.
Zotepine is a second generation antipsychotic drug, a substituted dibenzothiepine tricyclic molecule, with effects on dopamine, serotonin and noradrenaline receptors. This article reviews the relevant research studies on the drug based on a search of numerous medical databases for research and literature concerning zotepine and adverse reactions reported to the UK Medicines and Healthcare Products Regulatory Agency. There are double-blind trials demonstrating zotepine as an efficacious antipsychotic with a safe side effect profile that compares favourably with other atypical antipsychotics with regard to metabolic effects and movement disorders. There are some open label studies suggesting usefulness in treatment resistant schizophrenia, but larger, double-blind studies are required.
Green
Ben
B
Cheadle Royal Hospital, Cheshire, UK.
D016907:Adverse Drug Reaction Reporting Systems; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003988:Dibenzothiepins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D011941:Receptors, Adrenergic / Q000187:drug effects / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D006113:United Kingdom
D014150:Antipsychotic Agents; D003988:Dibenzothiepins; D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; C022172:zotepine